Related Experiment Videos
Simultaneous expression of CD2 on a B-cell, small lymphocytic neoplasm
A L Viciana1, F C Lancet, W Chamizo
1University of Miami School of Medicine, Department of Pathology, Florida 33101.
Cytometry
|March 15, 1994
Summary
This study identified a rare B-cell chronic lymphocytic leukemia (B-CLL) that also expressed the T-cell marker CD2. This CD2 expression correlated with a more aggressive disease course, suggesting prognostic value.
Area of Science:
- Hematology
- Immunophenotyping
- Oncology
Background:
- B-cell chronic lymphocytic leukemia (B-CLL) is a common lymphoid malignancy.
- Standard diagnosis relies on immunophenotyping and genetic analysis.
- T-cell markers are typically absent in B-cell malignancies.
Observation:
- An unusual B-cell chronic lymphocytic leukemia case co-expressed the T-cell marker CD2.
- Cytofluorographic, immunohistologic, and gene rearrangement analyses confirmed B-cell origin.
- No other T-cell restricted markers were detected.
Findings:
- CD2 expression in this B-CLL case was associated with a more aggressive clinical course.
- This contrasts with the typically indolent behavior of B-CLL and small lymphocytic lymphoma.
- Previous reports suggest CD2 may indicate aggressive behavior in small lymphocytic neoplasms.
Implications:
- Surface phenotypic analysis, including CD2 expression, can aid in identifying hematopoietic neoplasms.
- CD2 expression may serve as a prognostic marker for B-cell chronic lymphocytic leukemia.
- Immunophenotypic analysis offers valuable prognostic information beyond simple diagnosis.